Adaptive Biotechnologies Corp (NAS:ADPT)
$ 6.13 -0.25 (-3.92%) Market Cap: 941.56 Mil Enterprise Value: 838.75 Mil PE Ratio: 0 PB Ratio: 4.20 GF Score: 81/100

Adaptive Biotechnologies Corp at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 14, 2021 / 03:00PM GMT
Release Date Price: $36.27 (-3.28%)
Tejas Rajeev Savant
Morgan Stanley, Research Division - Equity Analyst

(inaudible) Healthcare Conference. I'm Tejas Savant and i cover the life science tools and diagnostics sector here at Morgan Stanley.

Delighted to have Adaptive join us today. And representing the company is Chad Robins, CEO. Welcome, Chad. Before we get started, just a quick safe harbor. Please see Morgan Stanley research disclosure website at www.morganstanley.com/researchclosures. If you have any questions, please reach out to your sales rep.

Questions & Answers

Tejas Rajeev Savant;Chad M. Robins
Morgan Stanley, Research Division - Equity Analyst;Adaptive Biotechnologies Corporation - Co-Founder,

So with that, Chad, maybe just to set the stage. Can you give us a quick overview of what you're most proud about in terms of Adaptive's achievements year-to-date? And what are the most important strategic priorities you have penciled in heading into '22?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot